Gabriel N. Hortobagyi, M.D., F.A.C.P.

Page last modified on: August 14, 2008

Gabriel N. Hortobagyi, M.D., F.A.C.P. chairs the department of breast medical oncology and directs the Breast Cancer Research Program at the University of Texas M.D. Anderson Cancer Center, where he also serves as professor of medicine and holds the Nellie B. Connally Chair in Breast Cancer.

Dr. Hortobagyi's research includes combination chemotherapy regimens, presurgical chemotherapy, and targeted therapies for all stages of breast cancer. He has contributed more than 800 articles to scientific journals, authored and co-authored 13 books, and contributed over 130 chapters to textbooks.

For his efforts in breast cancer research, Dr. Hortobagyi has received worldwide honors. In 2001, President Jacques Chirac named him Chevalier of the Order of la Legion d'Honneur de France. In 2003, Dr. Hortobagyi received the Glen Robbins Award in Breast Cancer Research from the New York Cancer Society and the Metropolitan Breast Cancer Group, and the Bristol-Myers Squibb 2003 Horizon Scientific Award. The Mexican Society of Oncology named him the 2005 World Leader in Oncology.

Dr. Hortobagyi was elected President of the American Society of Clinical Oncology (ASCO) for the 2006-2007 term. He chairs the Breast Committee of the Southwest Oncology Group as well as the Data and Safety Monitoring Committee of the National Surgical Adjuvant Breast and Bowel Project.

Of his role on the Breastcancer.org Professional Advisory Board, Dr. Hortobagyi says, "Being a part of Breastcancer.org helps me focus all my professional activities where they belong: on the patient."

Email Updates

Stay informed about current research, online events, and more.

Back to top

Breastcancer.org 7 East Lancaster Avenue, 3rd Floor Ardmore, PA 19003

Learn more about our commitment to your privacy

© 2008 Breastcancer.org - All rights reserved.

Breastcancer.org is a non-profit organization dedicated to providing information and community to those touched by this disease. Learn more about our commitment to providing complete, accurate, and private breast cancer information.